MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Multidisciplinary central team deployed to assist Gujarat with epidemiological, environmental, and laboratory investigations of AES cases
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
The initiative aimed to reach and support individuals suffering from epilepsy through early detection and effective disease management
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
Subscribe To Our Newsletter & Stay Updated
